Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker LKFT · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Jul 13, 2026 | Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell T… NCT06652633 · Hematological Malignancies GLPG CAR T-cell therapy | LKFT Lakefront Biotherapeutics NV | Phase 3 | Recruiting | 546 | Jul 2039 | Registry ↗ |
| Jun 30, 2026 | A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Ly… NCT06561425 · Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Lymphomas… GLPG5101 | LKFT Lakefront Biotherapeutics NV | Phase 1/2 | Terminated | 130 | May 27, 2026 | Registry ↗ |
| May 14, 2026 | A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants Wit… NCT05856448 · Systemic Lupus Erythematosus GLPG3667, Placebo | LKFT Lakefront Biotherapeutics NV | Phase 2 | Completed | 186 | Oct 8, 2025 | Registry ↗ |
| May 14, 2026 | A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults Wit… NCT05695950 · Dermatomyositis GLPG3667, Placebo | LKFT Lakefront Biotherapeutics NV | Phase 2 | Completed | 40 | Oct 13, 2025 | Registry ↗ |
| Oct 9, 2024 | Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Ac… NCT03201445 · Inflammatory Bowel Disease Filgotinib, Placebo | LKFT Lakefront Biotherapeutics NV | Phase 2 | Terminated | 139 | Nov 20, 2020 | Registry ↗ |
| Oct 4, 2024 | A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Coli… NCT05479058 · Ulcerative Colitis Filgotinib, Placebo | LKFT Lakefront Biotherapeutics NV | Phase 3 | Terminated | 22 | Oct 9, 2023 | Registry ↗ |
| Sep 19, 2024 | Drug-drug Interaction Study with GLPG3667 and Itraconazole in Healthy Subjects NCT05272683 · Healthy GLPG3667, Itraconazole | LKFT Lakefront Biotherapeutics NV | Phase 1 | Completed | 14 | Apr 1, 2022 | Registry ↗ |
| Sep 19, 2024 | Drug-drug Interaction Study with GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects NCT04971746 · Healthy Pirfenidone, GLPG4716 | LKFT Lakefront Biotherapeutics NV | Phase 1 | Completed | 58 | May 9, 2022 | Registry ↗ |
| Sep 19, 2024 | A Study to Evaluate How Well Single and Multiple Doses of GLPG3121-modified Release Formulation Are… NCT04856358 · Healthy GLPG3121, Placebo | LKFT Lakefront Biotherapeutics NV | Phase 1 | Completed | 50 | Nov 8, 2021 | Registry ↗ |
| Sep 19, 2024 | Drug-drug Interaction Study with GLPG3970 and Sulfasalazine in Adult, Healthy Subjects NCT04720183 · Healthy Sulfasalazine, GLPG3970 | LKFT Lakefront Biotherapeutics NV | Phase 1 | Completed | 8 | Apr 21, 2021 | Registry ↗ |
| Sep 19, 2024 | A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3970 NCT04106297 · Healthy, Psoriasis GLPG3970 oral solution, Placebo oral solution | LKFT Lakefront Biotherapeutics NV | Phase 1 | Completed | 100 | Mar 5, 2021 | Registry ↗ |
| Sep 19, 2024 | A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667 NCT04097938 · Healthy GLPG3667 oral suspension, Placebos | LKFT Lakefront Biotherapeutics NV | Phase 1 | Completed | 52 | Mar 4, 2020 | Registry ↗ |
| Aug 22, 2024 | A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidn… NCT04578548 · Autosomal Dominant Polycystic Kidney Disease GLPG2737, Placebo | LKFT Lakefront Biotherapeutics NV | Phase 2 | Terminated | 66 | Dec 14, 2022 | Registry ↗ |
| Jul 10, 2024 | Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease NCT02914600 · Crohn's Disease Filgotinib, Placebo | LKFT Lakefront Biotherapeutics NV | Phase 3 | Terminated | 1,188 | Aug 1, 2023 | Registry ↗ |
| Jun 4, 2024 | Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participants NCT02065700 · Rheumatoid Arthritis Filgotinib | LKFT Lakefront Biotherapeutics NV | Phase 2 | Completed | 739 | Jan 19, 2023 | Registry ↗ |
| Apr 30, 2024 | Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoi… NCT03926195 · Rheumatoid Arthritis, Psoriatic Arthritis Filgotinib, Placebo | LKFT Lakefront Biotherapeutics NV | Phase 2 | Completed | 109 | Aug 14, 2020 | Registry ↗ |
| Mar 1, 2024 | First-in-Human Single Ascending Dose of GLPG0492 NCT01130818 · Healthy GLPG0492, placebo | LKFT Lakefront Biotherapeutics NV | Phase 1 | Completed | 28 | Aug 2010 | Registry ↗ |
| Dec 18, 2023 | Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Acti… NCT02914561 · Crohn's Disease Filgotinib, Placebo | LKFT Lakefront Biotherapeutics NV | Phase 3 | Completed | 1,372 | Nov 11, 2022 | Registry ↗ |
| Nov 29, 2023 | Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotini… NCT06043739 · Bioavailability Filgotinib, Filgotinib | LKFT Lakefront Biotherapeutics NV | Phase 1 | Completed | 12 | Oct 27, 2023 | Registry ↗ |
| Sep 18, 2023 | A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With A… NCT04700280 · Primary Sjögren Syndrome GLPG3970, Placebo | LKFT Lakefront Biotherapeutics NV | Phase 2 | Terminated | 31 | Oct 28, 2021 | Registry ↗ |
| Jan 27, 2023 | A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ul… NCT04577794 · Ulcerative Colitis GLPG3970, Placebo | LKFT Lakefront Biotherapeutics NV | Phase 2 | Completed | 31 | May 17, 2021 | Registry ↗ |
| Jul 29, 2022 | A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmon… NCT03733444 · Idiopathic Pulmonary Fibrosis GLPG1690, Placebo | LKFT Lakefront Biotherapeutics NV | Phase 3 | Terminated | 781 | Mar 30, 2021 | Registry ↗ |
| Jul 29, 2022 | A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary… NCT03711162 · Idiopathic Pulmonary Fibrosis GLPG1690, Placebo | LKFT Lakefront Biotherapeutics NV | Phase 3 | Terminated | 525 | Mar 30, 2021 | Registry ↗ |
| Jul 18, 2022 | A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Mo… NCT04577781 · Rheumatoid Arthritis GLPG3970, Placebo | LKFT Lakefront Biotherapeutics NV | Phase 2 | Completed | 28 | Mar 26, 2021 | Registry ↗ |
| Jun 30, 2022 | Evaluation of Mass Balance and Absolute Bioavailability of GLPG3667 NCT05335447 · Healthy GLPG3667 capsule, [14C]-GLPG3667 solution for infusion | LKFT Lakefront Biotherapeutics NV | Phase 1 | Completed | 5 | Jun 3, 2022 | Registry ↗ |
| Apr 21, 2022 | An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis. NCT03320876 · Psoriatic Arthritis filgotinib | LKFT Lakefront Biotherapeutics NV | Phase 2 | Terminated | 122 | Jun 30, 2021 | Registry ↗ |
| Mar 29, 2022 | A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis NCT03976648 · Systemic Sclerosis GLPG1690 | LKFT Lakefront Biotherapeutics NV | Phase 2 | Terminated | 31 | Apr 13, 2021 | Registry ↗ |
| Feb 14, 2022 | A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult… NCT04976270 · Healthy GLPG3667, Placebo | LKFT Lakefront Biotherapeutics NV | Phase 1 | Completed | 23 | Jan 14, 2022 | Registry ↗ |
| Feb 1, 2022 | A Study to Evaluate How Well Single and Multiple Doses of GLPG4399 Are Tolerated in Healthy, Adult… NCT04653467 · Healthy GLPG4399 oral suspension, GLPG4399 capsules | LKFT Lakefront Biotherapeutics NV | Phase 1 | Completed | 88 | Jan 10, 2022 | Registry ↗ |
| Nov 24, 2021 | Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects NCT05030857 · Healthy GLPG4716, Midazolam | LKFT Lakefront Biotherapeutics NV | Phase 1 | Completed | 19 | Nov 13, 2021 | Registry ↗ |
| Oct 21, 2021 | A Study Evaluating the Effects of GLPG3970 Given as Oral Treatment for 12 Weeks in Adults With Syst… NCT04700267 · Systemic Lupus Erythematosus GLPG3970 film-coated tablet, Placebo film-coated tablet | LKFT Lakefront Biotherapeutics NV | Phase 1 | Terminated | 11 | Oct 6, 2021 | Registry ↗ |
| Sep 14, 2021 | A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmon… NCT03725852 · Idiopathic Pulmonary Fibrosis GLPG1205, Placebo | LKFT Lakefront Biotherapeutics NV | Phase 2 | Completed | 68 | Jul 21, 2020 | Registry ↗ |
| Jul 28, 2021 | A Study to Assess Efficacy and Safety of GLPG1972/S201086 in Participants With Knee Osteoarthritis NCT03595618 · Osteoarthritis GLPG1972, Placebo | LKFT Lakefront Biotherapeutics NV | Phase 2 | Completed | 932 | Jul 14, 2020 | Registry ↗ |
| Jul 23, 2021 | Evaluation of Mass Balance and Absolute Bioavailability of GLPG3970 NCT04907149 · Healthy GLPG3970 film-coated tablet, [14C]GLPG3970 solution for inf… | LKFT Lakefront Biotherapeutics NV | Phase 1 | Completed | 6 | Jul 12, 2021 | Registry ↗ |
| May 27, 2021 | A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Mo… NCT04594928 · Plaque Psoriasis GLPG3667, Placebo | LKFT Lakefront Biotherapeutics NV | Phase 1 | Completed | 30 | May 4, 2021 | Registry ↗ |
| May 11, 2021 | A Study in Healthy Male Volunteers Investigating the Safety, Absorption and Elimination of Single D… NCT04575818 · Healthy GLPG4059 oral suspension, Placebo | LKFT Lakefront Biotherapeutics NV | Phase 1 | Terminated | 32 | Apr 8, 2021 | Registry ↗ |
| May 4, 2021 | A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis NCT03798366 · Systemic Sclerosis GLPG1690, Placebo | LKFT Lakefront Biotherapeutics NV | Phase 2 | Completed | 33 | May 21, 2020 | Registry ↗ |
| Mar 25, 2021 | A Study to Assess Relative Bioavailability of and Effect of Food on a New Oral Tablet Formulation o… NCT04708184 · Healthy GLPG3970 oral solution, GLPG3970 tablet | LKFT Lakefront Biotherapeutics NV | Phase 1 | Completed | 12 | Feb 25, 2021 | Registry ↗ |
| Mar 25, 2021 | Evaluation of Mass Balance and Absolute Bioavailability of GLPG1205 NCT04704739 · Healthy GLPG1205 film-coated tablets, [14C]-GLPG1205 solution for i… | LKFT Lakefront Biotherapeutics NV | Phase 1 | Completed | 12 | Mar 2, 2021 | Registry ↗ |
| Mar 3, 2021 | Drug-drug Interaction Study With GLPG3667 and Midazolam in Healthy Subjects NCT04736927 · Healthy GLPG3667, Midazolam | LKFT Lakefront Biotherapeutics NV | Phase 1 | Completed | 14 | Feb 25, 2021 | Registry ↗ |
| Jan 5, 2021 | A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical C… NCT03864627 · Atopic Dermatitis MOR106, Placebo | LKFT Lakefront Biotherapeutics NV | Phase 2 | Terminated | 33 | Feb 27, 2020 | Registry ↗ |
| Dec 22, 2020 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Healthy Japanese… NCT04532567 · Healthy GLPG1205, Placebo | LKFT Lakefront Biotherapeutics NV | Phase 1 | Completed | 32 | Dec 10, 2020 | Registry ↗ |
| Dec 16, 2020 | Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DAR… NCT01894516 · Rheumatoid Arthritis GLPG0634, Placebo | LKFT Lakefront Biotherapeutics NV | Phase 2 | Completed | 287 | Mar 5, 2015 | Registry ↗ |
| Nov 17, 2020 | Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participant… NCT01888874 · Rheumatoid Arthritis GLPG0634, Placebo | LKFT Lakefront Biotherapeutics NV | Phase 2 | Completed | 599 | Feb 18, 2015 | Registry ↗ |
| Nov 6, 2020 | Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in… NCT02738801 · Idiopathic Pulmonary Fibrosis GLPG1690 600 mg QD, Placebo QD | LKFT Lakefront Biotherapeutics NV | Phase 2 | Completed | 23 | May 2, 2017 | Registry ↗ |
| Mar 19, 2020 | A Study Investigating the Safety, Absorption and Elimination of GLPG3312, a New Drug in the Treatme… NCT03800472 · Healthy GLPG3312 IR, Placebo | LKFT Lakefront Biotherapeutics NV | Phase 1 | Completed | 95 | Mar 10, 2020 | Registry ↗ |
| Mar 18, 2020 | A Study to Test Safety, Tolerability, and the Way the Body Absorbs, Distributes, and Gets Rid of a… NCT03689829 · Healthy, Atopic Dermatitis MOR106, Placebo | LKFT Lakefront Biotherapeutics NV | Phase 1 | Terminated | 44 | Mar 2, 2020 | Registry ↗ |
| Mar 18, 2020 | A Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics (PK)/Pharmacodynamics (PD) of… NCT03568071 · Atopic Dermatitis MOR 106, Placebo | LKFT Lakefront Biotherapeutics NV | Phase 2 | Terminated | 207 | Mar 3, 2020 | Registry ↗ |
| Jan 13, 2020 | A Study in Healthy Volunteers to Compare Different Tablet Formulations of the Test Medicine, GLPG19… NCT04137341 · Healthy GLPG1972 - A, GLPG1972 - B | LKFT Lakefront Biotherapeutics NV | Phase 1 | Completed | 18 | Dec 13, 2019 | Registry ↗ |
| Nov 20, 2019 | A Study in Healthy Male Volunteers to Test How the Test Medicine GLPG1972 is Taken up by the Body W… NCT04136327 · Healthy GLPG1972 film-coated tablets, [14C]-GLPG1972 solution for i… | LKFT Lakefront Biotherapeutics NV | Phase 1 | Completed | 6 | Oct 21, 2019 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:28 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances